Effects of Fasinumab on Peripheral Nerve Function in OA pain
Research type
Research Study
Full title
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients with Pain due to Osteoarthritis of the Hip or Knee
IRAS ID
245856
Contact name
Nicholas Probert
Contact email
Sponsor organisation
Regeneron Pharmaceuticals, Inc.
Eudract number
2017-004921-33
ISRCTN Number
ISRCTN00000000
Clinicaltrials.gov Identifier
Clinicaltrials.gov Identifier
103245, IND: Number
Duration of Study in the UK
2 years, 1 months, 10 days
Research summary
Fasinumab is currently being studied for treatment of pain due to Osteoarthritis (OA) of the hip or knee and chronic low back pain (CLBP). Fasinumab is a fully-human monoclonal antibody (a type of protein) that blocks a substance called nerve growth factor (NGF); also called an anti-NGF drug. NGF is a protein that causes pain. Blocking NGF may reduce pain due to OA of the hip and knee.
The main purpose of this study is to determine the effect of fasinumab compared to placebo (an inactive drug) on peripheral nerves in participants with pain due to OA of hip or knee.
The study includes screening, pre-randomisation (before being assigned to study drug or placebo), Treatment period and follow-up period. Participation in study may last up to 64 weeks excluding initial 40 days of screening and pre-randomisation period. Participants will be required to make at least 10 visits to the study site, and answer 2 phone calls from the study team.
This study will include about 180 participants in approximately 65 sites in North America, Europe and South Africa.
REC name
North West - Greater Manchester Central Research Ethics Committee
REC reference
18/NW/0683
Date of REC Opinion
17 Oct 2018
REC opinion
Favourable Opinion